Skin Substitute LCDs: Where the Coverage Rules Stand

On December 24, 2025, the Centers for Medicare & Medicaid Services (CMS) withdrew the national coverage policy for skin substitute grafts and cellular and tissue-based products (CTPs) that was scheduled to take effect January 1, 2026. That policy would have replaced each MAC's own coverage list with a single national list naming specific products as covered or not covered. The withdrawal did not bring back the coverage landscape that existed before the policy was drafted. Coverage decisions reverted to whatever rule already existed in each Medicare Administrative Contractor (MAC) jurisdiction, while a separate CMS payment rule for 2026 took effect on schedule. For any practice billing a skin substitute application, the gap between what Medicare will cover and what it will pay is now the audit exposure.

The December 2025 LCD Withdrawal

CMS's own fact sheet states that, effective immediately, its A/B Medicare Administrative Contractors withdrew the Local Coverage Determinations for Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers that were scheduled to become effective January 1, 2026. Those Local Coverage Determinations (LCDs) would have created a single national coverage list naming specific products as covered or not covered, with coverage of the remaining products left to each MAC's discretion. None of that took effect. Coverage instead reverts to whatever LCD, if any, already governed a given jurisdiction before December 24, 2025. That continuity follows from the fact sheet itself: the withdrawal reached only the LCDs scheduled to take effect January 1, 2026, not a MAC's earlier, already-effective policy. A jurisdiction without a product-specific LCD falls back to Medicare's general reasonable-and-necessary standard under Section 1862(a)(1)(A) of the Social Security Act, reviewed claim by claim. A provider billing the identical product in two different states can reach two different coverage outcomes.

The CY2026 Payment Rule CMS Left in Place

The CY2026 Medicare Physician Fee Schedule final rule (CMS-1832-F) set a single national payment rate for skin substitutes of $127.14 per square centimeter in both the physician office and hospital outpatient department setting, corrected from an initially published $127.28 in a November 28, 2025 Federal Register notice. The same rule reclassifies skin substitutes that are not FDA Biologics License Application (BLA) products as incident-to supplies rather than drugs or biologicals, and it ends wastage billing for these products: a discarded portion is not payable under any circumstance, and the JW and JZ modifiers, which apply only to drugs and biologicals, do not apply to incident-to supply claims. CMS has stated the changes are projected to cut Medicare spending on skin substitutes by close to 90 percent. None of this payment mechanic was touched by the December 2025 withdrawal.

The LCD withdrawal changed what Medicare will cover. It did not change what Medicare will pay, and the two now move on separate tracks.

Documentation and Audit Risk Under the Split

Separating the coverage test from the payment rule gives an auditor two independent grounds to deny a claim: the product or indication failed the jurisdiction's coverage test, or the billing did not match the incident-to and no-waste rules that took effect January 1, 2026. A durable defense file documents medical necessity and wound measurement at each encounter, consistent with the wound measurement documentation an auditor expects to see, ties that record to the debridement performed before graft application, and supports every entry with a signature log identifying the treating clinician. Where coverage is uncertain under a jurisdiction's reasonable-and-necessary standard, an Advance Beneficiary Notice preserves the practice's ability to bill the patient directly if Medicare denies the claim after the fact.

Health Law Alliance's attorneys have overseen 2,000+ audits and handled 5,000+ matters, with 25+ years of experience.

Why Early Legal Counsel Is Critical

It is critical that wound care providers promptly retain experienced healthcare defense counsel upon receiving an audit notice, a prepayment review request, or any other government or MAC inquiry tied to skin substitute billing. Early legal intervention can protect the provider's rights, ensure appropriate responses to government and contractor requests, avoid inadvertent admissions, preserve relevant defenses, and allow counsel to communicate with investigators or contractors on the provider's behalf. Delaying legal representation can significantly affect the outcome of a matter and expose the provider to unnecessary risk.

How Health Law Alliance Can Help

Health Law Alliance represents wound care providers and CTP suppliers in skin substitute audits, prepayment review, and MAC coverage disputes nationwide. Our attorneys track each jurisdiction's coverage policy and the CY2026 payment rules together, because a defense built on only one side of that split misses the claim's real exposure. If your practice is facing a skin substitute audit or a denial tied to these changes, contact our wound care audit defense attorneys for a free, confidential consultation.